This suggests that passive immunization with tau antibodies can be a viable therapeutic target and which the CSF amount of p-tau262/356 or in the microtubule binding domain (MTBD) can function a helpful biomarker of tau pathology to watch tau therapeutics in scientific trials.They shown this partnership with both pathological specimens and by tau P